Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today.
NEW YORK — Patients with post-refractive corneas are not necessarily excluded from undergoing premium IOL implantation, according to an expert at OSN New York.